Stereotaxis, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Stereotaxis, Inc. (NYSE: STXS) designs, manufactures, and markets robotic systems, instruments, and information solutions for interventional laboratories focused on minimally invasive endovascular interventions, particularly in electrophysiology and cardiology; core products include the Genesis RMN and GenesisX RMN systems for precise magnetic navigation of catheters and guidewires in cardiac ablation procedures, the Odyssey platform for real-time procedural information management and workflow integration, the MAGiC catheter for robotically navigated radiofrequency ablation, disposable accessories such as QuikCAS for automated catheter advancement and Vdrive for device stability, and imaging systems like the Stereotaxis Imaging Model S x-ray; the company also offers related consumables including magnetic ablation catheters and irrigation sleeves. Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis operates globally across the United States, Europe, Asia, and other regions through direct sales, distributors, and strategic partnerships with hospitals and electrophysiologists targeting complex arrhythmias such as atrial fibrillation and ventricular tachycardia. Recent developments include a definitive agreement in May 2024 to acquire Access Point Technologies for catheter manufacturing capabilities expected to add approximately $5 million in annual revenue, a $50 million sales agreement with Roth Capital Partners in August 2025 to fund product expansion and commercialization, a $12.5 million registered direct offering in July 2025 led by a strategic partner, FDA clearance and initial clinical success for the MAGiC Sweep and MAGiC catheter with peer-reviewed results published in July 2025 demonstrating 100% acute efficacy, first-in-human procedures and live demonstrations of the GenesisX system at the 2025 Heart Rhythm Society meeting highlighting its weekend installation advantages, regulatory progress toward CE Mark under MDR and advancements in the Emagin family of endovascular devices including Emagin 5F, and integrations with systems from Abbott, NVIDIA for AI enhancements, and others to broaden robotic applications in underserved markets.
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
Stereotaxis Announces First MAGiC Procedures in the United States
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis, Inc. (STXS) M&A Call Transcript
Stereotaxis Announces Definitive Agreement to Acquire Robocath
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Reports 2025 Full Year Financial Results
Stereotaxis Inc. (NYSEAMERICAN:STXS) Short Interest Update
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026